PharmX TechnologiesASX:PHX 40 EBIT per Share is A$-0.00 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 527 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 189753.13% on this metric.
PharmX Technologies's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PharmX Technologies's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of PharmX Technologies was 37.00% per year. The lowest was 37.00% per year. And the median was 37.00% per year.
ASX:PHX's 3-Year EBIT Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 11.9 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
PharmX Technologies (ASX:PHX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PharmX Technologies EBIT per Share Related Terms
PharmX Technologies EBIT per Share Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmX Technologies (ASX:PHX) has a EBIT per Share of A$-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PharmX Technologies and its competitors. According to the industry distribution chart, PharmX Technologies ranks #999999 out of 527 companies in the Healthcare Providers & Services industry.
Is PharmX Technologies' EBIT per Share too high?
PharmX Technologies' current EBIT per Share is A$-0.00. Based on the distribution chart, PharmX Technologies ranks #999999 out of 527 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #999999 out of 527 companies for EBIT per Share. This places PharmX Technologies in the lower half of its industry. The industry median EBIT per Share is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.90, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current EBIT per Share is A$-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.11 — trading 57.1% above its estimated fair value. The current EBIT per Share is A$-0.00. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current EBIT per Share is A$-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.11 is trading 57.1% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
EBIT per Share: A$-0.00
GF Value™: A$0.07 vs. price of A$0.11 (57.1% above fair value)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score
Get the complete analysis for ASX:PHX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
